Sandra E. Dunn
- Cancer Research top 1%
- Oncology top 2%
- Cancer Cells and Metastasis 17
- HER2/EGFR in Cancer Research 15
- Cancer-related Molecular Pathways 7
- Molecular Biology top 2%
- RNA Research and Splicing 22
- Melanoma and MAPK Pathways 10
- PI3K/AKT/mTOR signaling in cancer 8
- Aging top 5%
- Genetics top 2%
- Glioma Diagnosis and Treatment 16
-
- Growth Hormone and Insulin-like Growth Factors 7
- Co-authors
- Anna L. StratfordKaiji HuJ. Carl BarrettAbbas FotovatiArezoo AstaneheJennifer LawCathy LeeJill E. Kucab
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Sandra E. Dunn
97 papers receiving 5.0k citations
Peers
Comparison fields: 5 of 115
- Cancer Research 1.1k
- Oncology 1.5k
- Molecular Biology 3.5k
- Aging 74
- Genetics 418
Countries citing papers authored by Sandra E. Dunn
This map shows the geographic impact of Sandra E. Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra E. Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra E. Dunn more than expected).
Fields of papers citing papers by Sandra E. Dunn
This network shows the impact of papers produced by Sandra E. Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra E. Dunn. The network helps show where Sandra E. Dunn may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sandra E. Dunn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 9 | |
| 4 | 2013 | 45 | |
| 5 | 2012 | 31 | |
| 6 | 2011 | 69 | |
| 7 | 2011 | 14 | |
| 8 | 2011 | 46 | |
| 9 | 2010 | 144 | |
| 10 | 2010 | 42 | |
| 11 | 2010 | 46 | |
| 12 | 2010 | 43 | |
| 13 | 2009 | 45 | |
| 14 | 2009 | 48 | |
| 15 | 2009 | 81 | |
| 16 | 2008 | 339 | |
| 17 | 2008 | 97 | |
| 18 | Targeting Y-box binding protein-1 (YB-1) in Her-2 over-expressing breast cancer cells induces apoptosis via the signal transducer and activator or transcription-3 (STAT3) pathway and suppresses tumor growth. | 2008 | 1 |
| 19 | 2006 | 136 | |
| 20 | 2005 | 249 |
About Sandra E. Dunn
Sandra E. Dunn is a scholar working on Genetics, Oncology and Cancer Research, having authored 99 papers that have together received 5.1k indexed citations. Recurring topics across this work include RNA Research and Splicing (22 papers), Cancer Cells and Metastasis (17 papers), Glioma Diagnosis and Treatment (16 papers), HER2/EGFR in Cancer Research (15 papers), Melanoma and MAPK Pathways (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Growth Hormone and Insulin-like Growth Factors (7 papers) and Cancer-related Molecular Pathways (7 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.5k citations) and Molecular Biology (3.5k citations). Sandra E. Dunn has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Anna L. Stratford, Kaiji Hu, J. Carl Barrett, Abbas Fotovati, Arezoo Astanehe, Jennifer Law, Cathy Lee, Jill E. Kucab, Michaël Pollak and Maggie C.U. Cheang. Their work appears in journals such as Cancer Research, Oncogene, Oncotarget, Breast Cancer Research and Stem Cells.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.